ITALFARMACO
Manufacturing · Italy · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Viale Fulvio Testi 330, Milano, Lombardy...Phone Number
+39 264431Website
www.italfarmaco.comRevenue
$169.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ITALFARMACO
Italfarmaco SpA is a private multinational pharmaceutical group founded in 1938, based in Milan, Italy, dedicated to researching, developing, and producing high-quality prescription and over-the-counter drugs. The company focuses on innovative solutions for disease prevention, management, and cure, with a particular emphasis on rare diseases. Italfarmaco aims to improve healthcare accessibility and effectiveness through pioneering research and development in key therapeutic areas. Their commitment to science and patient well-being drives their mission to create impactful treatments for patients and society.Explore more
ITALFARMACO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ITALFARMACO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ITALFARMACO launches new products
Check out if ITALFARMACO is spiking on competitors!
Check if ITALFARMACO has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ITALFARMACO has new funding data
Website visits: Recent activity has been detected on your website
ITALFARMACO, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ITALFARMACO had a recent Job posting/layoffs
Earning: See what the market has to say on ITALFARMACO recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ITALFARMACO
Recommended Actions
Find VP level buyers at ITALFARMACO
Find more new buyers
Company Profile Activity
Activity Insights
ITALFARMACO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ITALFARMACO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ITALFARMACO.
ITALFARMACO Tech Stack
A closer look at the technologies used by ITALFARMACO
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
ITALFARMACO News & Media
Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
MILAN, Italy, July 7, 2026 – Italfarmaco S.p.A. today announced the presentation of new data from its clinical development programme for givinostat in patients with Duchenne muscular dystrophy (DMD) at the 19th International Congress on Neuromuscular Diseases (ICNMD) 2026, taking place from July 7-11 in Florence, Italy. The presentations highlight findings from the pivotal Phase 3 EPIDYS trial and its ongoing open-label extension (OLE) study, including quantitative magnetic resonance imaging (MRItalfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
MILAN, Italy, June 10, 2026 – Italfarmaco S.p.A. today announced that Health Canada has accepted for review the New Drug Submission (NDS) for givinostat (Duvyzat®) for the treatment of Duchenne muscular dystrophy (DMD). Health Canada has granted givinostat Priority Review status, a designation reserved for drugs that may provide a significant improvement in the benefit-risk profile over existing therapies. “Families affected by Duchenne muscular dystrophy in Canada currently have limited accessITF Therapeutics LLC Presents New Data and Analyses on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2026 MDA Clinical and Scientific Conference
Long-term observations from the givinostat clinical development program further characterize safety profile in patients with Duchenne muscular dystrophy Additional analyses highlight new findings related to decline in muscle contractile area and median age at loss of ambulation with...ITF Therapeutics LLC Announces Multiple Data Presentations at 2026 MDA Clinical and Scientific Conference
Presenting ten abstracts including observations on long-term safety, disease progression, and decline in muscle contractile area with givinostat Encore oral presentation also highlights analyses from the givinostat clinical development program on weight-based flexible dosing CONCORD, Mass....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ITALFARMACO
Sign Up For FreeTo access detailed company insights
Italfarmaco SpA is a private multinational pharmaceutical group founded in 1938, based in Milan, Italy, dedicated to researching, developing, and producing high-quality prescription and over-the-counter drugs. The company focuses on innovative solutions for disease prevention, management, and cure, with a particular emphasis on rare diseases. Italf... Read More
